Cyplasin Biomedical

Contact
cyplasin.com
+17804692975

Cyplasin Biomedical Ltd.

9650- 20 Avenue,
T6N 1G1 Edmonton
Canada

Phone

cyplasin.com
Contact
Profile Products News
Contact

About Cyplasin Biomedical

Founded in 2007 and headquartered in Edmonton, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company's current goal is to develop and commercialize the anticancer properties of Cyplasin-SC(TM) against skin cancer and melanoma.

Read more about Cyplasin Biomedical
Facts about Cyplasin Biomedical
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Cyplasin Biomedical

Product portfolio

Show all

News about Cyplasin Biomedical

Cyplasin Biomedical

17-Feb-2009 | business & finance

Cyplasin Biomedical Ltd., announces Licensing of Cyplasin technology

Cyplasin Biomedical Ltd., announced that it has completed the granting of a worldwide exclusive license to Bioxen Ltd for its Cyplasin technology for ...

Read news
Cyplasin Biomedical

03-Jun-2008 | research and development

Cyplasin Biomedical Ltd Announces Australian Patent for the recombinant production of its Antitumor Protein

Cyplasin Biomedical Ltd announced that its Australian Patent application Nr 2002361168 has been granted on April 29th, 2008 and the notice of acceptance ...

Read news
Cyplasin Biomedical

27-May-2008 | research and development

Cyplasin Biomedical Ltd Announces Japanese Patent for its Antitumor Protein

Cyplasin Biomedical Ltd announced that its Japanese Patent application Nr Hei 9-516992 has been granted. The claims cover the characterization of a ...

Read news
Cyplasin Biomedical

06-Nov-2007 | research and development

Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin

Cyplasin Biomedical Ltd today announced that its U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA ...

Read news
Cyplasin Biomedical

09-Oct-2007 | research and development

Cyplasin-SC Enters Next Phase of Efficacy Animal Testing

In recent third party validated cell based laboratory tests, Cyplasin-SC(TM) has shown a unique toxicity to many tumor cells, including human melanoma ...

Read news
Cyplasin Biomedical

07-Sep-2007 | research and development

Cyplasin-SC kills melanoma cells, even derived from different patients but leaves normal human cells unharmed

It is well known that many cancer types - or even the same cancer in different patients - show different sensitivities to a given therapeutic treatment. In ...

Read news
Show more news about Cyplasin Biomedical

Here you will find Cyplasin Biomedical Ltd.